Content :
R&D Portfolio
A rich, innovative and balanced R&D portfolio
113 products under development
- 47 products in phases IIb and III
- 7 products in phase IIa
- 59 products in preclinical and phase I
Number of products per domain and phase
|
Preclinical |
Phase I |
Phase IIa |
Phase IIb |
Phase III |
Total |
| Metabolism |
4 |
2 |
0 |
4 |
0 |
10 |
| Cardiovascular |
4 |
2 |
0 |
4 |
2 |
12 |
| Thrombosis |
2 |
0 |
0 |
2 |
2 |
6 |
| Central Nervous System |
4 |
6 |
1 |
4 |
5 |
20 |
| Internal Medicine |
7 |
6 |
2 |
2 |
1 |
18 |
| Oncology |
6 |
5 |
0 |
0 |
8 |
19 |
| Vaccines |
4 |
7 |
4 |
3 |
10 |
28 |
| Total |
31 |
28 |
7 |
19 |
28 |
113 |
R&D portfolio presented on February 12, 2008
|
